600380 健康元
已收盘 08-01 15:00:00
资讯
新帖
简况
保健品概念盘中跳水，健康元跌0.86%
市场透视 · 07-31 06:34
保健品概念盘中跳水，健康元跌0.86%
健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放
互动易 · 07-29 07:36
健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放
健康元：针对COPD的TSLP单抗正在推进二期临床，目前进度居国内前列
格隆汇 · 07-29 07:34
健康元：针对COPD的TSLP单抗正在推进二期临床，目前进度居国内前列
健康元：合并报表计算逻辑导致净利润低于丽珠集团
证券之星 · 07-29 07:34
健康元：合并报表计算逻辑导致净利润低于丽珠集团
健康元：持续加大创新药研发投入，多个1类创新药进入临床关键阶段
证券之星 · 07-29 07:34
健康元：持续加大创新药研发投入，多个1类创新药进入临床关键阶段
生物疫苗概念盘中拉升，一品红涨4.45%
市场透视 · 07-28
生物疫苗概念盘中拉升，一品红涨4.45%
每周股票复盘：健康元（600380）药业集团股份有限公司董事会决议通过两项议案
证券之星 · 07-26
每周股票复盘：健康元（600380）药业集团股份有限公司董事会决议通过两项议案
健康元：延长第一期持股计划存续期并调整管理方式
公司公告 · 07-25
健康元：延长第一期持股计划存续期并调整管理方式
减肥药板块集体走强
深圳商报 · 07-22
减肥药板块集体走强
临床突破释放协同价值，健康元盘中大涨近8%，双靶点IL-17A/F单抗III期达终点
每经网 · 07-22
临床突破释放协同价值，健康元盘中大涨近8%，双靶点IL-17A/F单抗III期达终点
合成生物概念盘中拉升，健康元涨4.64%
市场透视 · 07-22
合成生物概念盘中拉升，健康元涨4.64%
健康元：聚焦抗耐药超级细菌领域创新疗法
证券之星 · 07-17
健康元：聚焦抗耐药超级细菌领域创新疗法
港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可
智通财经 · 07-17
港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可
单抗概念盘中拉升，丽珠集团涨停
市场透视 · 07-16
单抗概念盘中拉升，丽珠集团涨停
健康元涨5.02%创近8个月新高 资金博弈与政策预期共振
智选洞察 · 07-16
健康元涨5.02%创近8个月新高 资金博弈与政策预期共振
健康元：公司聚焦核心领域，研发管线进展的价值将随时间释放
互动易 · 07-15
健康元：公司聚焦核心领域，研发管线进展的价值将随时间释放
健康元：构建COPD系统性创新布局
证券之星 · 07-15
健康元：构建COPD系统性创新布局
健康元：呼吸疾病治疗领域竞争推动临床价值提升
证券之星 · 07-15
健康元：呼吸疾病治疗领域竞争推动临床价值提升
健康元获得外观设计专利授权：“包装盒（鹰牌花旗参60袋2025年春节礼盒）”
证券之星 · 07-14
健康元获得外观设计专利授权：“包装盒（鹰牌花旗参60袋2025年春节礼盒）”
默沙东百亿大收购再掀风口，健康元“领先一步”布局吸入药
财中社 · 07-14
默沙东百亿大收购再掀风口，健康元“领先一步”布局吸入药
加载更多
公司概况
公司名称：
健康元药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-08
主营业务：
健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。
发行价格：
24.80
{"stockData":{"symbol":"600380","market":"SH","secType":"STK","nameCN":"健康元","latestPrice":12.57,"timestamp":1754031600000,"preClose":12.7,"halted":0,"volume":36920997,"delay":0,"changeRate":-0.0102,"floatShares":1829000000,"shares":1829000000,"eps":0.7558,"marketStatus":"已收盘","change":-0.13,"latestTime":"08-01 15:00:00","open":12.7,"high":13.06,"low":12.53,"amount":471000000,"amplitude":0.0417,"askPrice":12.57,"askSize":515,"bidPrice":12.56,"bidSize":856,"shortable":0,"etf":0,"ttmEps":0.7558,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754271000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.7,"symbolType":"stock","openAndCloseTimeList":[[1754011800000,1754019000000],[1754024400000,1754031600000]],"highLimit":13.97,"lowLimit":11.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1829453386,"isCdr":false,"pbRate":1.59,"roa":"--","peRate":16.631384,"roe":"2.99%","epsLYR":0.74,"committee":0.199693,"marketValue":22996000000,"turnoverRate":0.0202,"status":1,"floatMarketCap":22996000000},"requestUrl":"/m/hq/s/600380","defaultTab":"news","newsList":[{"id":"2555060810","title":"保健品概念盘中跳水，健康元跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555060810","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555060810?lang=zh_cn&edition=full","pubTime":"2025-07-31 14:34","pubTimestamp":1753943693,"startTime":"0","endTime":"0","summary":"07月31日，保健品概念盘中跳水，截至14点34分，保健品概念整体指数下跌1.02%，报1320.430点。从个股上来看，该概念的成分股中，健康元跌0.86%，葵花药业、百龙创园、晨光生物跌幅居前。从资金上来看，截止发稿，保健品概念概念主力净流入为-3.61亿，其中振东制药受到资金热捧，主力净流入5827.73万；拉长时间线来看，该板块近20日主力资金净流入-28.47亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731143453a6cafd6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731143453a6cafd6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","600380","BK0046","BK0239","605016","BK0028","BK0114","BK0188","BK0226"],"gpt_icon":0},{"id":"2555039426","title":"健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2555039426","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555039426?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:36","pubTimestamp":1753774560,"startTime":"0","endTime":"0","summary":"目前已上市的 PDE3/4 双靶点抑制剂创新药，其核心优势在于依托 PDE3 靶点发挥较强的支气管扩张作用，而在抗炎方面的效果相对有限，无法完全满足 COPD 患者对炎症控制的需求。因此，我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放，恰好能弥补现有治疗中 “抗炎效果不足” 的短板，为患者提供更精准的炎症控制选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","BK0077","159992","BK0188","BK0239","600380","BK0028","BK0114"],"gpt_icon":0},{"id":"2555703845","title":"健康元：针对COPD的TSLP单抗正在推进二期临床，目前进度居国内前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2555703845","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555703845?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:34","pubTimestamp":1753774488,"startTime":"0","endTime":"0","summary":"两款药物分别针对不同年龄段患者设计，有望为全人群流感治疗提供更适配的选择。2）在呼吸慢病领域，针对 COPD 的TSLP单抗正在推进二期临床，目前进度居国内前列；全球 FIC 靶点 PREP 抑制剂已完成一期临床，正在推进二期临床；该布局延续了公司在 COPD 赛道的深耕 。4）自免领域的 IL-17A/F 单抗三期临床已达到主要终点，该药物优势显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291535209724e2e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507291535209724e2e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0114","BK0188","BK0239","BK0046","BK0077","600380","BK0028"],"gpt_icon":0},{"id":"2555885033","title":"健康元：合并报表计算逻辑导致净利润低于丽珠集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2555885033","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555885033?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:34","pubTimestamp":1753774466,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元07月29日在投资者关系平台上答复投资者关心的问题。公司合并财务报表中，对丽珠集团的净利润核算需按持股比例确认归母净利润。由于公司并非全资持有丽珠集团，仅将所持股权对应比例的净利润纳入合并归母净利润，剩余部分归属其他股东，出现如您所提的情形，是合并报表在计算逻辑上的正常现象，并非仅计算了分红利润。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900020523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","000513"],"gpt_icon":0},{"id":"2555033830","title":"健康元：持续加大创新药研发投入，多个1类创新药进入临床关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2555033830","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555033830?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:34","pubTimestamp":1753774456,"startTime":"0","endTime":"0","summary":"公司近年来持续加大在创新药领域的研发投入，当前已有多个1类创新药和具有全球差异化竞争力的创新药项目进入临床关键阶段截止现在已布局二十余款1类创新药，其中超过10款已进入二期临床及以后阶段，各项目均按计划有序推进。COPD作为高发慢性呼吸疾病，患者数量庞大且持续增长，现有治疗中难以有效控制炎症，导致症状持续加重，反复急性发作等问题尚未解决，这些药物有望为这一领域带来新的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900020517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","600380","BK0114","BK0188","159992","BK0028","BK0077","BK1574","BK0239","BK1161","06978"],"gpt_icon":0},{"id":"2554741734","title":"生物疫苗概念盘中拉升，一品红涨4.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554741734","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554741734?lang=zh_cn&edition=full","pubTime":"2025-07-28 09:36","pubTimestamp":1753666598,"startTime":"0","endTime":"0","summary":"07月28日，生物疫苗概念盘中拉升，截至09点36分，生物疫苗概念整体指数上涨0.52%，报2475.810点。从个股上来看，该概念的成分股中，一品红涨4.45%，生物股份、科前生物、健康元涨幅居前。从资金上来看，截止发稿，生物疫苗概念主力净流入为-3061.63万，其中塞力医疗受到资金热捧，主力净流入1505.21万；拉长时间线来看，该板块近20日主力资金净流入-27.12亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728093638a6c4dce2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728093638a6c4dce2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603716","BK0077","159657","BK0046","BK0239","BK0188","300723","688526","600201","BK0028","BK0196","BK0012","BK0185","600380"],"gpt_icon":0},{"id":"2554075711","title":"每周股票复盘：健康元（600380）药业集团股份有限公司董事会决议通过两项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2554075711","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554075711?lang=zh_cn&edition=full","pubTime":"2025-07-27 03:17","pubTimestamp":1753557430,"startTime":"0","endTime":"0","summary":"截至2025年7月25日收盘，健康元报收于12.26元，较上周的12.19元上涨0.57%。本周，健康元7月22日盘中最高价报13.02元。健康元当前最新总市值224.29亿元，在化学制药板块市值排名26/150，在两市A股市值排名767/5148。若存续期届满前未减持完毕，则需再次召开持有人会议和董事会审议后续事宜。该议案已由第一期持股计划第二次持有人会议审议通过，并根据2021年第二次临时股东大会授权，无需再次提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072700000499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0077","BK0028","BK0188","BK0239","600380","BK0046"],"gpt_icon":0},{"id":"2554384763","title":"健康元：延长第一期持股计划存续期并调整管理方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2554384763","media":"公司公告","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554384763?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:53","pubTimestamp":1753433603,"startTime":"0","endTime":"0","summary":"健康元公告，公司九届董事会十一次会议审议通过《关于第一期中长期事业合伙人持股计划延长存续期的议案》及《关于第一期中长期事业合伙人持股计划调整管理方式的议案》，同意将第一期持股计划存续期延长12个月至2026年8月3日，并将管理模式调整为公司自行管理。关联董事回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170005a6c15c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170005a6c15c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","600380","BK0114","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2553271257","title":"减肥药板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2553271257","media":"深圳商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553271257?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:44","pubTimestamp":1753202680,"startTime":"0","endTime":"0","summary":"7月22日，减肥药板块集体走强。截至收盘，丽珠集团上涨7.62%，博瑞医药上涨5.49%。这是WHO首次将减肥药物纳入官方推荐。据行业研究，GLP-1类药物凭借“降糖+减重”双效机制，已成为肥胖治疗首选，2030年全球市场规模或突破千亿美元。6月24日于美国举行的糖尿病协会第85届科学会议上，博瑞医药公布了其自主研发的GLP-1R/GIPR双靶点激动剂BGM0504的两项II期临床研究数据。研究表明，该药物在2型糖尿病患者中降糖疗效良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723004444954d341b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723004444954d341b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603087","600380","BK0077","BK0188","688166","BK0046","605116","BK0028","BK0114","688690"],"gpt_icon":0},{"id":"2553542286","title":"临床突破释放协同价值，健康元盘中大涨近8%，双靶点IL-17A/F单抗III期达终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2553542286","media":"每经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553542286?lang=zh_cn&edition=full","pubTime":"2025-07-22 11:23","pubTimestamp":1753154632,"startTime":"0","endTime":"0","summary":"7月22日，健康元股价盘中一度上涨近8%，市场情绪快速升温。7月21日晚，健康元公告，其自主研发的重组抗IL-17A/F人源化单抗注射液在针对中重度斑块状银屑病的III期临床试验中达到主要研究终点，并在多个关键疗效指标上“头对头”优于国际对照产品，正式开启国产双靶点IL-17生物制剂的商业化冲刺。据悉，该创新药由健康元和丽珠共同出资设立的生物药平台开发，健康元直接及间接持股比例达53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722112828954c31fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722112828954c31fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","01513","BK0188","600380","BK0239","BK0114","BK0028","BK0046"],"gpt_icon":0},{"id":"2553528865","title":"合成生物概念盘中拉升，健康元涨4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553528865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553528865?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:40","pubTimestamp":1753148443,"startTime":"0","endTime":"0","summary":"07月22日，合成生物概念盘中拉升，截至09点40分，合成生物概念整体指数上涨0.51%，报1269.840点。从个股上来看，该概念的成分股中，健康元涨4.64%，凯莱英、博瑞医药、奥锐特涨幅居前。从资金上来看，截止发稿，合成生物概念主力净流入为-2.29亿，其中牧原股份受到资金热捧，主力净流入3276.57万；拉长时间线来看，该板块近20日主力资金净流入-77.14亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094043954c06ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094043954c06ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","06821","BK0188","BK0239","605116","BK0046","BK0114","BK0028","688166","BK0077"],"gpt_icon":0},{"id":"2552248882","title":"健康元：聚焦抗耐药超级细菌领域创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2552248882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552248882?lang=zh_cn&edition=full","pubTime":"2025-07-17 17:57","pubTimestamp":1752746231,"startTime":"0","endTime":"0","summary":"公司与腾盛博药合作的这款产品，是针对多重耐药革兰阴性菌感染的创新疗法，聚焦于抗耐药超级细菌领域，这一领域目前存在较大的临床未满足需求，也是全球公共卫生关注的重点方向。未来若两类产品均成功上市，在临床应用中可针对呼吸系统疾病及其相关感染并发症形成覆盖，为患者提供更全面的治疗方案支持。后续，公司将持续围绕重大公共健康及临床未满足需求，聚焦以“呼吸”为主的创新战略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700029962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","600380","BK0114","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2552172451","title":"港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2552172451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552172451?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:40","pubTimestamp":1752720051,"startTime":"0","endTime":"0","summary":"消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和商业化。腾盛博药美国已收取首付款，未来在达成相关里程碑事件时，将收到额外的开发和商业化里程碑付款，并将根据BRII-693的产品净销售额按约定比例获得销售分成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","BK1161","BK0077","BK1574","BK0239","BK1587","BK0046","BK0188","BK0028","02137","600380"],"gpt_icon":0},{"id":"2551117165","title":"单抗概念盘中拉升，丽珠集团涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2551117165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551117165?lang=zh_cn&edition=full","pubTime":"2025-07-16 14:19","pubTimestamp":1752646793,"startTime":"0","endTime":"0","summary":"07月16日，单抗概念盘中拉升，截至14点19分，单抗概念整体指数上涨2.00%，报2550.550点。从个股上来看，该概念的成分股中，丽珠集团涨停，奥赛康、健康元2只股涨幅超过5%。从资金上来看，截止发稿，单抗概念概念主力净流入为4.90亿，其中华海药业受到资金热捧，主力净流入1.08亿；拉长时间线来看，该板块近20日主力资金净流入6.59亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716141953a44df76c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716141953a44df76c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600380","BK0114","BK0077","BK0187","BK0046","BK0028","600521","BK0239","BK0188","000513"],"gpt_icon":0},{"id":"2551117835","title":"健康元涨5.02%创近8个月新高 资金博弈与政策预期共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2551117835","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551117835?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:50","pubTimestamp":1752645006,"startTime":"0","endTime":"0","summary":"健康元股价今日表现强势，截至13点49分，公司股价报12.34元/股，涨幅达5.02%，创近8个月以来新高。资金博弈与政策预期共振健康元近日净流入与资金面高频波动密切相关。截至7月16日13时49分，该股日内涨超5%，主力资金净流入2386.9万元，较前两个交易日累计净流出1305.1万元实现逆转。中报季市场风格切换加剧板块资金腾挪，医药板块整体承压背景下，健康元7月4日至8日主力资金在2428万元净流入与2133万元净流出间剧烈切换。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135008a44deba7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716135008a44deba7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0028","BK0114","BK0046","600380","BK0188","BK0239"],"gpt_icon":0},{"id":"2551154175","title":"健康元：公司聚焦核心领域，研发管线进展的价值将随时间释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2551154175","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551154175?lang=zh_cn&edition=full","pubTime":"2025-07-15 15:39","pubTimestamp":1752565140,"startTime":"0","endTime":"0","summary":"有投资者向健康元提问， 公司回购注销了好几次，为什么还是不受市场认可，股价还是一直低迷？公司研发投入那么多，超出太不成比例了。科伦同样研发出来了很多BD公司回答表示，您好！股价受宏观环境、行业周期、市场情绪等多重因素影响，公司回购注销是基于长期发展信心，旨在传递价值信号，市场认知需时间沉淀。医药研发具有高投入、长周期特性，成果转化需逐步验证。公司聚焦核心领域，研发管线进展的价值将随时间释放。行业企业发展路径各异，公司坚持差异化深耕，始终相信价值终将回归本质。公司将以稳健的研发策略、可持续的商业模式，持续为投资者创造长期回报，感谢您的关注与支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715154551a6aa89b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715154551a6aa89b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","600380","BK0046","BK0239","BK0114","BK0077","BK0028"],"gpt_icon":0},{"id":"2551151400","title":"健康元：构建COPD系统性创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2551151400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551151400?lang=zh_cn&edition=full","pubTime":"2025-07-15 15:34","pubTimestamp":1752564856,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：看到默沙东最近花了100亿收购了一个做COPD的公司，公司之前也有介绍过PDE4这个管线，跟默沙东收购那款类似吗？近期默沙东以百亿美元收购VeronaPharma的交易，引发资本市场对呼吸领域尤其是慢阻肺创新治疗的高度关注。其核心资产ensifentrine作为吸入型PDE3/4抑制剂，虽可同时实现支气管舒张与抗炎，但临床实践中，抗炎始终是COPD治疗的核心难点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500020878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0188","BK0046","BK0028","BK0077","BK0114","BK0239"],"gpt_icon":0},{"id":"2551295151","title":"健康元：呼吸疾病治疗领域竞争推动临床价值提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2551295151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551295151?lang=zh_cn&edition=full","pubTime":"2025-07-15 15:34","pubTimestamp":1752564855,"startTime":"0","endTime":"0","summary":"呼吸疾病治疗领域市场空间广阔，不同企业基于技术路径差异开展创新，行业竞争是推动临床价值提升的常态，不同机制、不同剂型的药物可在临床中形成互补关系，不是单一竞品关系。行业竞争的核心是临床价值的比拼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500020875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0239","BK0114","BK0028","BK0077","BK0046","BK0188"],"gpt_icon":0},{"id":"2551133678","title":"健康元获得外观设计专利授权：“包装盒（鹰牌花旗参60袋2025年春节礼盒）”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551133678","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551133678?lang=zh_cn&edition=full","pubTime":"2025-07-15 02:40","pubTimestamp":1752518454,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示健康元新获得一项外观设计专利授权，专利名为“包装盒”，专利申请号为CN202430712762.9，授权日为2025年7月15日。今年以来健康元新获得专利授权7个，较去年同期增加了75%。通过天眼查大数据分析，健康元药业集团股份有限公司共对外投资了30家企业，参与招投标项目169次；财产线索方面有商标信息1406条，专利信息156条，著作权信息31条；此外企业还拥有行政许可106个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500002248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","BK0239","BK0028","600380","BK0188","BK0077"],"gpt_icon":0},{"id":"2551810188","title":"默沙东百亿大收购再掀风口，健康元“领先一步”布局吸入药","url":"https://stock-news.laohu8.com/highlight/detail?id=2551810188","media":"财中社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551810188?lang=zh_cn&edition=full","pubTime":"2025-07-14 18:54","pubTimestamp":1752490440,"startTime":"0","endTime":"0","summary":"就在不久前，全球医药巨头默沙东宣布以100亿美元收购Verona Pharma，其核心资产是一款名为Ohtuvayre的吸入型PDE3/4双靶点抑制剂。健康元药业集团，早在默沙东出手之前，已前瞻性布局了吸入型PDE4创新疗法，并在“精准抗炎”“局部给药”方面取得关键技术突破。可以说，健康元并未拘泥于某一条热门路径，而是在用全局视角重新定义这个疾病的治疗格局。在全球制药巨头掀起吸入制剂浪潮时，健康元已经布好了自己的棋局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714190902a6a8a72c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714190902a6a8a72c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","600380","BK0028","BK0239","BK0114","BK0046","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1754031651511,"stockEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.1557},{"period":"3month","weight":0.2179},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2224},{"period":"ytd","weight":0.1455}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":0.0334},{"period":"3month","weight":0.0897},{"period":"6month","weight":0.0992},{"period":"1year","weight":0.2159},{"period":"ytd","weight":0.0661}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健康元药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79702人(较上一季度减少0.18%)","perCapita":"22953股","listingDate":"2001-06-08","address":"广东省深圳市南山区高新区北区朗山路17号健康元药业集团大厦","registeredCapital":"182945万元","survey":" 健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。","listedPrice":24.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康元,600380,健康元股票,健康元股票老虎,健康元股票老虎国际,健康元行情,健康元股票行情,健康元股价,健康元股市,健康元股票价格,健康元股票交易,健康元股票购买,健康元股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}